Anthony G. Quinn is CEO & President at Aeglea BioTherapeutics, Inc. (AGLE). They have made 12 open-market trades across 2 companies since 2017, most recently 2026-02-09.
12 open-market purchases totalling $3.6M since 2017, never a sale. Across 12 scored buys the stock is up 2.4% at ninety days, and 2.9 points ahead of the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 58% |
| Avg Move | -0.6% | +0.4% | +2.4% |
| Alpha | -1.1% | -1.9% | +2.9% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GBIO | BUY | 2025-01-10 | 2025-01-14 | $0.96 | $324K | -10.2% | -31.3% | -62.2% |
| GBIO | BUY | 2023-12-01 | 2023-12-05 | $1.41 | $250K | +39.9% | +32.9% | +93.0% |
| AGLE | BUY | 2022-03-16 | 2022-03-18 | $2.34 | $375K | -15.8% | -30.1% | -75.5% |
| AGLE | BUY | 2022-03-11 | 2022-03-15 | $1.94 | $562K | +17.6% | -0.5% | -62.9% |
| AGLE | BUY | 2021-12-09 | 2021-12-13 | $3.71 | $358K | +3.2% | +2.9% | -53.7% |
| AGLE | BUY | 2020-04-30 | 2020-05-04 | $4.75 | $784K | -17.7% | +12.4% | -14.7% |
| AGLE | BUY | 2019-06-12 | 2019-06-14 | $6.15 | $360K | -0.2% | +8.0% | +41.2% |
| AGLE | BUY | 2019-05-20 | 2019-05-22 | $6.77 | $334K | -6.1% | -5.7% | +16.7% |
| AGLE | BUY | 2019-02-15 | 2019-05-17 | $6.76 | $126K | -1.8% | -4.4% | +17.3% |
| AGLE | BUY | 2018-02-15 | 2018-12-10 | $7.05 | $21K | -13.3% | +6.0% | +1.0% |
| AGLE | BUY | 2017-12-06 | 2017-12-08 | $4.95 | $41K | -3.9% | -2.3% | +70.5% |
| AGLE | BUY | 2017-12-01 | 2017-12-05 | $4.86 | $83K | +0.4% | +17.3% | +58.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.